Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer

Cancer Biology and Therapy

Volumn 16, Issue 2, 2015, Pages 268-275

  Yuan, Dawei ^a   Li, Kang ^a   Zhu, Kun ^a   Yan, Rong ^a   Dang, Chengxue ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Biomarker; Colorectal cancer; MicroRNA; MiR 183; Plasma; Prognosis; Recurrence

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MICRORNA; MICRORNA 183; UNCLASSIFIED DRUG; MIRN183 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE EXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; TUMOR RECURRENCE; UPREGULATION; BLOOD; CANCER GRADING; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; TUMOR CELL LINE;

ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; UP-REGULATION;

EID: 84924569776     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2014.1002327     Document Type: Article

References (41)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin 2011; 61:69-90; PMID:21296855
2. Kraus S, Nabiochtchikov I, Shapira S, Arber N. Recent advances in personalized colorectal cancer research. Cancer Letters 2014; 347:15-21; PMID:24491406; http://dx.doi.org/10.1016/j.canlet.2014.01.025
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045-5
4. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8; PMID: 15944708; http://dx.doi.org/10.1038/nature03702
5. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-66; PMID:17060945; http://dx.doi.org/10.1038/nrc1997
6. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9:189-98; PMID:16530703; http://dx.doi.org/10.1016/j.ccr.2006.01.025
7. Iorio MV, Ferracin M, Liu C-G, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065-70; PMID:16103053; http://dx.doi.org/10.1158/0008-5472.CAN-05-1783.
8. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 2008; 105:10513-8; PMID:18663219; http://dx.doi.org/10.1073/pnas.0804549105
9. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18:997-1006; PMID:18766170; http://dx.doi.org/10.1038/cr.2008.282
10. Pierce ML, Weston MD, Fritzsch B, Gabel HW, Ruvkun G, Soukup GA. MicroRNA-183 family conservation and ciliated neurosensory organ expression. Evol Dev 2008; 10:106-13; PMID:18184361; http://dx.doi.org/10.1111/j.1525-142X.2007.00217.x
11. Abraham D, Jackson N, Gundara JS, Zhao J, Gill AJ, Delbridge L, Robinson BG, Sidhu SB. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res 2011; 17:4772-81; PMID:21622722; http://dx.doi.org/10.1158/1078-0432.CCR-11-0242
12. Xu X, Dong Z, Li Y, Yang Y, Yuan Z, Qu X, Kong B. The upregulation of signal transducer and activator of transcription 5-dependent microRNA-182 and microRNA-96 promotes ovarian cancer cell proliferation by targeting forkhead box O3 upon leptin stimulation. Int J Biochem Cell Biol 2013; 45:536-45; PMID: 23262295; http://dx.doi.org/10.1016/j.biocel.2012.12.010
13. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, Morlan BW, Riska SM, Boardman LA, Cunningham JM. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 2009; 9:401; PMID:19922656; http://dx.doi.org/10.1186/1471-2407-9-401
14. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, Sugihara K, Mori M. Over-and under-expressed microRNAs in human colorectal cancer. Int J Oncol 2009; 34:1069-75; PMID:19287964
15. Earle JS, Luthra R, Romans A, Abraham R, Ensor J, Yao H, Hamilton SR. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn 2010; 12:433-40; PMID:20413677; http://dx.doi.org/10.2353/jmoldx.2010.090154
16. Zhang Q-H, Sun H-M, Zheng R-Z, Li Y-C, Zhang Q, Cheng P, Tang Z-H, Huang F. Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. Gene 2013; 527:26-32; PMID:23791657; http://dx.doi.org/10.1016/j.gene.2013.06.006
17. Zhou T, Zhang G-J, Zhou H, Xiao H-X, Li Y. Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. Eur J Gastroenterol Hepatol 2014; 26:229-33; PMID:24150523; http://dx.doi.org/10.1097/MEG.0000000000000002
18. Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the us multi-society task force on colorectal cancer and the american cancer society∗,†. CA: Cancer J Clin 2006; 56:143-59; PMID:16737947; http://dx.doi.org/10.3322/canjclin.56.3.143
19. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10:704-14; PMID:19763153; http://dx.doi.org/10.1038/nrg2634
20. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee M-LT, Schmittgen TD. Detection of microRNA expression in human peripheral blood microvesicles. PloS one 2008; 3:e3694; PMID:19002258; http://dx.doi.org/10.1371/journal.pone.0003694
21. Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2012; 32:326-48; PMID: 22383180; http://dx.doi.org/10.1002/med.20215
22. Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Gen 2013; 4:116; PMID:23802013; http://dx.doi.org/10.3389/fgene.2013.00116
23. Zhi F, Cao X, Xie X, Wang B, Dong W, Gu W, Ling Y, Wang R, Yang Y, Liu Y. Identification of circulating micrornas as potential biomarkers for detecting acute myeloid leukemia. PloS one 2013; 8:e56718; PMID:23437222; http://dx.doi.org/10.1371/journal.pone.0056718
24. Yu H, Jiang L, Sun C, Guo L, Lin M, Huang J, Zhu L. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene 2014; 534:60-5; PMID:24404590; http://dx.doi.org/10.1016/j.gene.2013.10.024
25. Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P, Pospisil V, Stopka T. Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer 2014; 14:448; PMID:24938880; http://dx.doi.org/10.1186/1471-2407-14-448
26. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Müller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011; 77:1265. e9-. e16; PMID:NOT-FOUND; http://dx.doi.org/10.1016/j.urology.2011.01.020
27. Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Morimura R, Nagata H, Kosuga T, Iitaka D, Konishi H, Shiozaki A. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. British J Cancer 2011; 105:104-11; PMID:21673684; http://dx.doi.org/10.1038/bjc.2011.198
28. Zhu X, Lv M, Wang H, Guan W. Identification of circulating MicroRNAs as novel potential biomarkers for gastric cancer detection: a systematic review and meta-analysis. Dig Dis Sci 2014; 59:911-9; PMID:24337687; http://dx.doi.org/10.1007/s10620-013-2970-9
29. Fesler A, Jiang J, Zhai H, Ju J. Circulating microRNA Testing for the Early Diagnosis and Follow-up of Colorectal Cancer Patients. Mol Diagn Ther 2014; 18:303-8; PMID:24566942; http://dx.doi.org/10.1007/s40291-014-0089-0
30. Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X, Wang L. Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol 2012; 180:2440-51; PMID:22525461; http://dx.doi.org/10.1016/j.ajpath.2012.02.023
31. Lowery AJ, Miller N, Dwyer RM, Kerin MJ. Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer 2010; 10:502; PMID:20858276; http://dx.doi.org/10.1186/1471-2407-10-502
32. Sarver AL, Li L, Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res 2010; 70:9570-80; PMID:21118966; http://dx.doi.org/10.1158/0008-5472.CAN-10-2074
33. Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. Proc Natl Acad Sci 1996; 93:11831-6; PMID:NOT-FOUND; http://dx.doi.org/10.1073/pnas.93.21.11831
34. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFb1, PTEN, p53, and fibronectin. Cancer Gene ther 2005; 13:115-24; PMID:16138117; http://dx.doi.org/10.1038/sj.cgt.7700896
35. Krones-Herzig A, Mittal S, Yule K, Liang H, English C, Urcis R, Soni T, Adamson ED, Mercola D. Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res 2005; 65:5133-43; PMID:15958557; http://dx.doi.org/10.1158/0008-5472.CAN-04-3742
36. Pfütze K, Luo X, Burwinkel B. MicroRNA signatures as biomarkers of colorectal cancer. MicroRNAs Med 2013:329-42; http://dx.doi.org/10.1002/9781118300312.ch19
37. Pu XX, Huang Gl, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tian Y, Lin TY. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010; 25:1674-80; PMID:20880178; http://dx.doi.org/10.1111/j.1440-1746.2010.06417.x
38. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR, Zhang W. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PloS one 2011; 6:e17745; PMID:21445232; http://dx.doi.org/10.1371/journal.pone.0017745
39. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg 2014; 259:735-43; PMID:23982750; http://dx.doi.org/10.1097/SLA.0b013e3182a6909d
40. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Preven Res 2012; 5:492-7; PMID:22158052; http://dx.doi.org/10.1158/1940-6207.CAPR-11-0370
41. th ed). New York: NY: Springer, 2010.